advisorsecurities master

GLSIGreenwich LifeSciences, Inc.

CSNasdaq (XNAS)·USD

Identity

Security key
16073
Ticker
GLSI
Type
CSCommon Stock
Exchange
Nasdaq(XNAS)
Venue group
NASDAQ
Operating MIC
XNAS
Market
stocks
Locale
us
Currency
USD
Listed
2020-09-25
Round lot
100
Active
Yes
Last seen in a load
2026-08-14 20:49
Vendor updated
2026-08-13 06:09
Ticker root / suffix
GLSI

Detail

Enriched 2026-08-14 20:47

Market cap
$248,355,279.36
Shares outstanding (class)
14,678,208
Shares outstanding (weighted)
14,678,208
SIC
2834 PHARMACEUTICAL PREPARATIONS
Employees
13
Location
STAFFORD, TX
Description

Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9-amino-acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including breast cancers at low (1+), intermediate (2+), and high (3+ or overexpressing) levels.

Market cap and share counts drift.

Funds holding this security

Identifiers

Classification

Fund data